| scholarly article | Q13442814 |
| P2093 | author name string | Shi-Yong Sun | |
| Shuo Zhang | |||
| Taofeek K Owonikoko | |||
| Mingwei Chen | |||
| Hui Ren | |||
| Emily Anderson | |||
| Liang Deng | |||
| Guojing Zhang | |||
| Suresh S Ramalingam | |||
| Grant Wu | |||
| Puyu Shi | |||
| You-Take Oh | |||
| Benjamin Legendre | |||
| Guoqing Qian | |||
| P2860 | cites work | MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling | Q27851406 |
| AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer | Q27853158 | ||
| Rociletinib in EGFR-mutated non-small-cell lung cancer | Q27853159 | ||
| Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. | Q27853162 | ||
| Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics | Q28469345 | ||
| Thr 163 phosphorylation causes Mcl-1 stabilization when degradation is independent of the adjacent GSK3-targeted phosphodegron, promoting drug resistance in cancer | Q28484291 | ||
| BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations | Q28756824 | ||
| Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer | Q33740707 | ||
| Caspase-8 in apoptosis: the beginning of "the end"? | Q34143631 | ||
| Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas | Q36026392 | ||
| The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies | Q36104980 | ||
| EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors | Q36687288 | ||
| Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer | Q36775204 | ||
| Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. | Q37000646 | ||
| Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer | Q37177949 | ||
| Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy | Q37389181 | ||
| Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: a new era begins. | Q38119594 | ||
| Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance. | Q38504491 | ||
| Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors. | Q38506135 | ||
| Third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer | Q38684074 | ||
| Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment | Q38756221 | ||
| Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models | Q38887681 | ||
| The PI3 kinase inhibitor NVP-BKM120 induces GSK3/FBXW7-dependent Mcl-1 degradation, contributing to induction of apoptosis and enhancement of TRAIL-induced apoptosis | Q39170414 | ||
| Elevated expression of eukaryotic translation initiation factor 4E is associated with proliferation, invasion and acquired resistance to erlotinib in lung cancer | Q39413724 | ||
| FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR. | Q39571776 | ||
| Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors | Q39716418 | ||
| Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. | Q40486081 | ||
| MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol | Q40537978 | ||
| Extracellular signal-regulated kinases 1/2 are serum-stimulated "Bim(EL) kinases" that bind to the BH3-only protein Bim(EL) causing its phosphorylation and turnover | Q40606380 | ||
| Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. | Q40626751 | ||
| Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim. | Q40662652 | ||
| Mechanisms of apoptosis induced by the synthetic retinoid CD437 in human non-small cell lung carcinoma cells | Q40954596 | ||
| Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer | Q42815191 | ||
| High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression | Q44828642 | ||
| Differential effects of synthetic nuclear retinoid receptor-selective retinoids on the growth of human non-small cell lung carcinoma cells | Q73838303 | ||
| Regulatory phosphorylation of Bim: sorting out the ERK from the JNK | Q81833475 | ||
| P433 | issue | 21 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 6567-6579 | |
| P577 | publication date | 2017-08-01 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation | |
| P478 | volume | 23 |
| Q52594173 | Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model. |
| Q96129358 | Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer |
| Q91742514 | Concurrent inhibition of ErbB family and MEK/ERK kinases to suppress non-small cell lung cancer proliferation |
| Q92898855 | DYRK1A inhibition suppresses STAT3/EGFR/Met signalling and sensitizes EGFR wild-type NSCLC cells to AZD9291 |
| Q89818780 | Deguelin suppresses non-small cell lung cancer by inhibiting EGFR signaling and promoting GSK3β/FBW7-mediated Mcl-1 destabilization |
| Q60044511 | Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia |
| Q91844724 | ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib |
| Q64089193 | Emerging therapies for non-small cell lung cancer |
| Q91812931 | Formononetin inhibits tumor growth by suppression of EGFR-Akt-Mcl-1 axis in non-small cell lung cancer |
| Q91937343 | Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer |
| Q92060167 | Inhibition of EGFR Signaling and Activation of Mitochondrial Apoptosis Contribute to Tanshinone IIA-Mediated Tumor Suppression in Non-Small Cell Lung Cancer Cells |
| Q96122560 | MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of epidermal growth factor receptor-mutant lung cancers |
| Q92942818 | MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer |
| Q99210175 | Marked synergy by vertical inhibition of EGFR signaling in NSCLC spheroids shows SOS1 is a therapeutic target in EGFR-mutated cancer |
| Q60929137 | Overcoming Resistance to AC0010, a Third Generation of EGFR Inhibitor, by Targeting c-MET and BCL-2 |
| Q89461554 | Overcoming acquired resistance of EGFR-mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol |
| Q93062391 | Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589) |
| Q47450308 | Pharmacokinetic drug evaluation of osimertinib for the treatment of non-small cell lung cancer. |
| Q90590454 | Targeting apoptosis in cancer therapy |
| Q91254638 | Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer |
| Q64112445 | The Third-Generation EGFR Inhibitor, Osimertinib, Promotes c-FLIP Degradation, Enhancing Apoptosis Including TRAIL-Induced Apoptosis in NSCLC Cells with Activating EGFR Mutations |
| Q64115764 | The anti-tumor growth effect of a novel agent DMAMCL in rhabdomyosarcoma in vitro and in vivo |
| Q55223055 | The continued EGFR-TKI with cytotoxic chemotherapy at progression-poison or medicine? |
| Q50047476 | The irreversible ERBB1/2/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells. |
| Q49887956 | Third generation EGFR TKIs: current data and future directions |
| Q50104127 | Treatment of EGFR T790M-Positive Non-Small Cell Lung Cancer |
Search more.